Azafaros is set to initiate Phase 3 studies for its lead product nizubaglustat for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses later this year.
Founders
BGV
Company Description
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.